Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Purpose Anlotinib is widely used in the clinical treatment of non-small cell lung cancer
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …

Purpose This study was designed to assess the clinical efficacy and safety of anlotinib with
immunotherapy in advanced non-small cell lung cancer as third-line therapy. Patients and …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory
advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched …

Background The evidence of combined therapies of multi-target agents in first-line treatment
of advanced non-small cell lung cancer (NSCLC) was limited. This study aimed to evaluate …

Background This study evaluated the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …

Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …